Evidence map›Paper›PMID 25301705›Full record

ReviewBlood2014

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Peter Dreger, Johannes Schetelig, Niels Andersen, Paolo Corradini, Michel van Gelder, John Gribben, Eva Kimby, Mauricette Michallet, Carol Moreno, Stephan Stilgenbauer and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Maintenance therapy for chronic lymphocytic leukaemia.The Cochrane database of systematic reviews · 2024
    Review
  15. PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise.Blood and lymphatic cancer : targets and therapy · 2023
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Peter DregerDepartment Medicine V, University of Heidelberg, Heidelberg, Germany;
Johannes ScheteligDepartment Medicine I, University of Dresden, Dresden, Germany; German Bone Marrow Donor Registry, Tübingen, Germany;
Niels AndersenDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark;
Paolo CorradiniDepartment Hematology and Pediatric Onco-Hematology, Istituto Nazionale dei Tumori, Milan, Italy;
Michel van GelderDepartment Internal Medicine/Hematology, Maastricht University, Maastricht, The Netherlands;
John GribbenBarts Cancer Institute, Queen Mary University of London, London, United Kingdom;
Eva KimbyDepartment of Medicine/Hematology Unit, Karolinska Institute, Huddinge, Sweden;
Mauricette MichalletService d'Hématologie, Centre Hospitalier Lyon-Sud, Lyon, France;
Carol MorenoHospital de la Santa Creu Sant Pau, Barcelona, Spain;
Stephan StilgenbauerDepartment Medicine III, University of Ulm, Ulm, Germany; and.
Emili MontserratDepartment of Hematology, Hospital Clínic, University of Barcelona, Barcelona, Spain.
European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [<24 months] to chemoimmunotherapy, and/or presence of del[17p]/TP53 mutations). Currently, treatment algorithms for HR-CLL are being challenged by the introduction of novel classes of drugs. Among them, BCR signal inhibitors (BCRi) and B-cell lymphoma 2 antagonists (BCL2a) appear particularly promising. As a result of the growing body of favorable outcome data reported for BCRi/BCL2a, uncertainty is emerging on how to advise patients with HR-CLL about indication for and timing of HSCT. This article provides an overview of currently available evidence and theoretical considerations to guide this difficult decision process. Until the risks and benefits of different treatment strategies are settled, all patients with HR-CLL should be considered for treatment with BCRi/BCL2a. For patients who respond to these agents, there are 2 treatment possibilities: (1) performing an HSCT or (2) continuing treatment with the novel drug. Individual disease-specific and transplant-related risk factors, along with patient's preferences, should be taken into account when recommending one of these treatments over the other.

Indexed as

Stem Cell TransplantationAlgorithmsCell Transformation, NeoplasticClinical Trials as TopicDecision MakingDrug TherapyGenes, p53Graft vs Leukemia EffectHematopoietic Stem Cell TransplantationHumansImmunotherapyLeukemia, Lymphocytic, Chronic, B-CellPrognosisProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcrQuality of LifeBCR protein, humanProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-bcr

Identifiers

PMID25301705
PMCPMC4276025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.